RT Journal Article SR Electronic T1 Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.22.20108084 DO 10.1101/2020.05.22.20108084 A1 Muriel Lins A1 Jan Vandevenne A1 Muhunthan Thillai A1 Ben R. Lavon A1 Maarten Lanclus A1 Stijn Bonte A1 Rik Godon A1 Irvin Kendall A1 Jan De Backer A1 Wilfried De Backer YR 2020 UL http://medrxiv.org/content/early/2020/07/02/2020.05.22.20108084.abstract AB Background Mounting evidence supports the role of pulmonary hemodynamic alternations in the pathogenesis of COVID-19. Previous studies have demonstrated that changes in pulmonary blood volumes measured on CT are associated with histopathological markers of pulmonary vascular pruning, suggesting that quantitative HRCT analysis may eventually be useful in the assessment pulmonary vascular dysfunction more broadly.Methods Building upon previous work, automated HRCT measures of small blood vessel volume and pulmonary vascular density were developed. Scans from 103 COVID-19 patients and 108 healthy volunteers were analyzed and their results compared, with comparisons made both on lobar and global levels.Results Compared to healthy volunteers, COVID-19 patients showed significant reduction in BV5 (pulmonary blood volume contained in blood vessels of <5 mm2) expressed as BV5/(Total pulmonary blood volume) (p<0.0001), and significant increases in BV5_10 and BV 10 (pulmonary blood volumes contained in vessels between 5 and 10 mm2 and above 10 mm2, respectively) (p<0.0001). These changes were consistent across lobes.Conclusions COVID-19 patients display striking anomalies in the distribution of blood volume within the pulmonary vascular tree, consistent with increased pulmonary vasculature resistance in the pulmonary vessels below the resolution of HRCT.Competing Interest StatementBL, ML, SB, RG, IK, and JDB are employees of FLUIDDA, a company that develops and markets part of the technology described in this paper. The other authors have no financial relationships with any organization or company that might have an interest in the submitted work and received no direct funding from FLUIDDA. Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval was granted by the respective local committees from each site which provided patient data: AZ Sint-Maarten (Mechelen), Ziekenhuis Oost-Limburg (Genk), Royal Papworth Hospital, and Wenzhou Medical University. Data for healthy patients comparators were acquired from the COPDGene cohort (NCT00608764).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request